IGCCCG RISKTesticular Cancer Prognostic Grouping

Prognostic Tier

Assign IGCCCG Category

Note: Risk grouping differs between Seminoma and Non-Seminoma. Seminoma can only be "Good" or "Intermediate" (never "Poor" per IGCCCG criteria).

Prognostic Outlook

Good Risk

Clinical Strategy

Good risk group. Favorable prognosis; standard treatment with BEP x 3 or EP x 4 chemotherapy.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

All patients with metastatic (Stage II or III) germ cell tumors (testicular, extragonadal).

Required prior to starting frontline chemotherapy (typically BEP: Bleomycin, Etoposide, Cisplatin).

Requires histology (Seminoma vs. Non-seminoma), primary site, presence of visceral metastases, and post-orchiectomy tumor markers (AFP, hCG, LDH).

How it Works

Non-Seminoma Risk Groups

Risk Group	Criteria
Good Risk	Testis/retroperitoneal primary AND no non-pulmonary visceral mets AND low markers (S1).
Intermediate Risk	Testis/retroperitoneal primary AND no non-pulmonary visceral mets AND intermediate markers (S2).
Poor Risk	Mediastinal primary OR non-pulmonary visceral mets OR high markers (S3).

Seminoma Risk Groups

Seminomas can only be classified as "Good" or "Intermediate" risk. There is NO "Poor Risk" category for pure seminoma, regardless of marker levels or primary site.

Last Comprehensive Review: 2026

IGCCCG RISKTesticular Cancer Prognostic Grouping

Prognostic Tier

Assign IGCCCG Category

Note: Risk grouping differs between Seminoma and Non-Seminoma. Seminoma can only be "Good" or "Intermediate" (never "Poor" per IGCCCG criteria).

Prognostic Outlook

Good Risk

Clinical Strategy

Good risk group. Favorable prognosis; standard treatment with BEP x 3 or EP x 4 chemotherapy.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

All patients with metastatic (Stage II or III) germ cell tumors (testicular, extragonadal).

Required prior to starting frontline chemotherapy (typically BEP: Bleomycin, Etoposide, Cisplatin).

Requires histology (Seminoma vs. Non-seminoma), primary site, presence of visceral metastases, and post-orchiectomy tumor markers (AFP, hCG, LDH).

How it Works

Non-Seminoma Risk Groups

Risk Group	Criteria
Good Risk	Testis/retroperitoneal primary AND no non-pulmonary visceral mets AND low markers (S1).
Intermediate Risk	Testis/retroperitoneal primary AND no non-pulmonary visceral mets AND intermediate markers (S2).
Poor Risk	Mediastinal primary OR non-pulmonary visceral mets OR high markers (S3).

Seminoma Risk Groups

Seminomas can only be classified as "Good" or "Intermediate" risk. There is NO "Poor Risk" category for pure seminoma, regardless of marker levels or primary site.

Last Comprehensive Review: 2026

IGCCCG Risk (Testicular)

Prognostic Tier

Good Risk

When to Use

Clinical Use

How it Works

Non-Seminoma Risk Groups

Seminoma Risk Groups

Clinical Pearls

The S3 Marker Thresholds

Management Implication

The Evidence

Key Reference

International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers

In Recent Clinical News

IGCCCG Risk (Testicular)

Prognostic Tier

Good Risk

When to Use

Clinical Use

How it Works

Non-Seminoma Risk Groups

Seminoma Risk Groups

Clinical Pearls

The S3 Marker Thresholds

Management Implication

The Evidence

Key Reference

International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers

In Recent Clinical News